Hyperthermia Combined With Neoadjuvant Radiochemotherapy for LARC — PUTHRC-001  

Radiotherapy Clinical Trial

Official title: Deep Hyperthermia Combined With Neoadjuvant Concurrent Radiochemotherapy for Locally Advanced Rectal Cancer, PUTHRC-001：A Multi-Center, Open-Label, Randomized Controlled Study

Status Not yet recruiting

Clinical Trial Summary

The purpose of this study is to determine whether adding deep hyperthermia to neoadjuvant concurrent radiochemotherapy could improve T-downstaging rate for locally advanced rectal cancer (LARC).

Clinical Trial Description

The purpose of this study is to determine whether adding deep hyperthermia to neoadjuvant concurrent radiochemotherapy could improve T-downstaging rate for locally advanced rectal cancer (LARC). The sample size is 142. Patients with LARC (T3-4/N+) will be randomly divided into intervention group and control group. For intervention group, the neoadjuvant therapy is hyperthermia combined with concurrent radiochemotherapy. For control group, the neoadjuvant treatment is concurrent radiochemotherapy. T-downstaging rate will be used to evaluate the effectiveness of deep hyperthermia. T-downstaging is defined as the postoperative pathological T stage lower than the original T stage by imaging before treatment. ;

Related Conditions & MeSH terms

• Fever
• Hyperthermia
• Radiotherapy

• NCT number: NCT05070832
• Study type: Interventional
• Source: Peking University Third Hospital
• Contact: Hao Wang, Doctor
• Phone: 82264911
• Email: wanghaobysy@bjmu.edu.cn
• Status: Not yet recruiting
• Phase: N/A
• Start date: January 1, 2022
• Completion date: December 31, 2024